L&K Biomed financials at a glance

+ Portfolio

The revenue of L&K Biomed is reported as 29.90481 billion Won in the fiscal year 2023. The earnings were -115 Won per share in 2023, which was 88.37 higher than 2020. And about 4.52453 billion Won are reported as free cash flow in the financials of L&K Biomed 2023. No dividends were paid to the shareholders of the L&K Biomed stock KOSDAQ:A156100 in the financial year 2023.

₩29.90B

Revenue

₩-,115.00

Earnings Per Share

85.87%

Gross Margin %

₩2.10B

Free Cash Flow

Revenue

29,904.81

Earnings Per Share

-,115.00

Gross Margin %

85.87

Free Cash Flow

2,100.00

Financials

Year	Year	TTM	2023	2020	2017	2016
Rev.	Revenue	N/A	₩29.90B	₩18.54B	₩37.11B	₩34.45B
GM %	Gross Margin %	82.14%	85.87%	69.52%	46.30%	59.27%
OM	Operating Margin	2.98%	6.80%	-19.94%	-25.24%	7.00%
EPS	Earnings Per Share	₩-,125.99	₩-,115.00	₩-,989.00	₩-1,139.00	₩155.00
Div.	Dividends	N/A	₩0.00	₩0.00	₩0.00	₩0.00
PR %	Payout Ratio %	0	0	0	0	0
Sha.	Shares	N/AM	19.94M	13.24M	9.56M	9.93M
OCF	Operating Cash Flow	N/A	₩5.20B	₩-,776.70M	₩-4,918.43M	₩0.00M
FCF	Free Cash Flow	N/A	₩2.10B	₩-2,720.88M	₩-5,593.90M	₩0.00M
FCFS	Free Cash Flow Per Share	₩-48.10	₩-,213.94	₩-,248.80	₩-,704.81	₩-1,337.05

L&K Biomed financials at a glance

Financials

Discover